SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ELTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 14.23M
March 31, 2026 13.70M
December 31, 2025 12.81M
September 30, 2025 11.82M
June 30, 2025 11.95M
March 31, 2025 11.60M
December 31, 2024 12.93M
September 30, 2024 13.40M
June 30, 2024 13.77M
March 31, 2024 13.86M
December 31, 2023 13.86M
September 30, 2023 12.29M
June 30, 2023 9.962M
March 31, 2023 8.32M
Date Value
December 31, 2022 8.505M
September 30, 2022 11.04M
June 30, 2022 13.79M
March 31, 2022 16.94M
December 31, 2021 18.49M
September 30, 2021 17.40M
June 30, 2021 19.45M
March 31, 2021 20.54M
December 31, 2020 17.99M
September 30, 2020 19.01M
June 30, 2020 13.03M
March 31, 2020 7.598M
December 31, 2019 4.143M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Precigen, Inc. 84.93M
Agenus, Inc. 38.48M
Amgen, Inc. 7.019B
Anika Therapeutics, Inc. 52.67M
BioCryst Pharmaceuticals, Inc. 328.11M